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Tumor-free hosts often develop strong resistance to transplanted tumorcells after
active immunization (1). However, immunotherapy of hosts with well-established
cancers, i.e., cancers that have been growingprogressively for severalweeksor longer,
is rarely effective whether in patients or experimental animals (2). For example, it
has been shown that immunological resistance can be induced to an autologous
methylcholanthrene-induced murine tumorifthetumor is first completely removed
and the tumor-free mouse is "rested." The removed tumor, "stored" by transplanta-
tion in another mouse and then transplanted back into the original host, is rejected
(3). However, tumor rejection has not been induced in these mice while they were
bearing the established autologous primary tumors.
Even though the presence ofstrong tumor-specific rejection antigens on a partic-
ularprimarytumormaybe suggestedby rejection ofa tumortransplant inthetumor-
free secondary hosts, the presence of such strong rejection antigens may have nei-
therprevented nor inhibited thedevelopment ofthistumorin the original (primary)
host. Forexample inUVinduced tumors ofmice, thedistinctionbetweenaregressor
tumorand progressor tumor phenotype can only be made after the original tumor
has been transplanted into tumor-free hosts (4).' How antigenic tumor cells escape
immune destruction in the original host is not fully understood, but once they have
escaped and become establishedasa tumor then thehost may beimmunosuppressed
due to the tumorburden (5-8; for review see reference 2).2 While the mechanisms
This work was supported by a gift ofthe Passis family and by the National Institutes of Health grants
R37 CA-22677, P01 CA-19266, R01-37156, R01 CA-08366, R01 CA-45954, 1F32 CA-08366, ST32
HL-07665, and T32 GMO-7281.
Address correspondence to Dr. George A. Perdrizet, Department of Pathology, University of Chi-
cago, 5841 S. Maryland Ave., Box 414, Chicago, IL 60637.
1 In thesetransplant recipients, either progression or spontaneous regression of the tumormayoccur,
whilein the original host, both regressor andprogressor tumors show similar malignant behavior and
eventually kill. Thus, so-called "regressor" tumors do not undergo spontaneous regression in the pri-
mary host, and may therefore be equally important as "progressor" tumors from a therapeutic point
ofview. In addition, regressor tumors may be important for immunotherapy, because they may have
suitable target antigens when they grow as the primary tumor in the host.
2 This is indicated forexampleby the observation that mice with a progressively growingregressor
or progressor tumor graft fail to reject asecond challenge with highly antigenic UVinducedregressor
tumor cells (8). The established tumor and the tumor cells used for second challenge do not have to
share individually distinct tumor antigens, which points at a more generalized defect in the immune
response of these tumor-bearing animals to syngeneic highly immunogenic tumor cells.
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for the defect of tumor-bearing mice are not well understood, breaking the state
of immunological unresponsiveness of tumor-bearing individuals to cancer is a pre-
requisite for active or passive immunotherapy. It is known that tumor cells can pro-
duce immunosuppressive substances or induce immune suppression. If this were
important, then removing the tumor antigen from the tumor cell environment and
presenting it on nonmalignant normal cells might induce an immunity specific for
this antigen even in the tumor-bearing animal (TBA).'
To test this possibility, mice bearing progressively growing regressor or progressor
tumors (RETBA or PROTBA) received transplants of either normal or malignant
cells expressing the same highly immunogenic MHC class I antigen, designated
K216 . We show that mice bearing the K`-negative progressor tumor (PROTBA)
do not respond to highly immunogenic K"'-positive regressor tumor cells, but do
respond to nonmalignant transgenic cells or tissue grafts expressing the same K216
antigen. Furthermore, mice bearing the progressively growing K111-positive re-
gressor tumor (RETBA) also rejected K2"-positive skin, but this response had no
measurable effect on the established tumoreven though it expressed the same K`
target antigen as the rejected skin.' These findings are consistent with the idea that
immune responses may be induced in the TBA more effectively by presenting a tumor
antigen on normal rather than malignant tissue but that such manipulation alone
will not cause immunologic rejection of an established tumor.
Materials and Methods
Animals and Tumor Lines.
￿
C3H/HeN (MTV-), BALB/cAn, and C57BL/6 mice were ob-
tained from the National Cancer Institute Frederick Animal Production Facility, Bethesda,
MD. The skin tumor 1591-RE (9) was induced by UV irradiation and regresses when trans-
planted into normal C3H/HeN mice. Even though this tumor was reported to have origi-
nated in C3H/HeN (MTV -) (H-2k) mice (9) and expresses normal Kk and Dk MHC class
I antigens, this tumor also expresses three immunogenic MHC class I antigens designated
L9, D9, and K216 (10, 11). The coding regions ofthe genes for the first two antigens are 100%
homologous to L9 and D4 genes (11). The third, K216, does not represent K9 as determined
by comparison of a partial DNA sequence of K4 made available to us by Dr. Gilbert Jay
(National Cancer Institute, Bethesda, MD); the precise origin of the K216 gene is still un-
known, but it may well encode a normal alloantigen like the other two normal MHC class
I genes found in the 1591-RE tumor. Gene K216 carries the number 216 because it was des-
ignated gene 216 when isolated from a genomic library of the 1591 regressor tumor (10). It
is designated as a K gene because this MHC class I gene contains the 27 extra base pairs
(bp) in the intracytoplasmic domain characteristic for K genes. Furthermore, K216 lacks the
L- and D-specific nucleotides in the leader sequence of exon I and is >99% homologous to
Kk from a point 300 by 5' of exon 4 continuing 1,800 bases into the 3' untranslated region
(12). The K`6 gene encodes an antigen that alone is sufficient for tumor rejection by normal
C3H/HeN mice (13). This gene, along with the other two immunogenic class I antigens,
D9 and L4 of the 1591-RE tumor, is always lost when 1591-PRO progressor variants of the
tumor develop (13). The 1591-PRO tumor (alsodesignated 1591-PR04L or 1591VARS (13])
used in this study is one of the progressor variants observed in 5 out of 100 animals that
were challenged with fragments ofthe 1591-RE tumor (14). 1591-PRO will grow progressively
in -80% of normal mice aftersubcutaneous transplantation. This progressor variant when
s Abbreviations used in this ;taper: PRO, progressor; RE, regressor; TBA, tumor-bearing animal.
4 This method for generating regressor TBA provides a model for studying primary highly anti-
genicUV-induced tumors whichexhibit a regressor phenotype upon transplantation into tumor-freemice.PERDRIZET ET AL.
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transfected with the K216 gene (designated K216 tumor) is always rejected by normal mice
unless the K216 gene is lost (13). 5128-PRO and 5117-RE are recently described UVinduced
BALB/c tumors (15). P815 is a mastocytoma that arose spontaneously in DBA/2 mice. All
tumors were cultured in vitroin minimum essential medium containing 10% heat-inactivated
FCS (CMEM) (14).
Tansgenic Mice.
￿
The X phage clone K216 was restricted with Hind III and Sal I and the
fragment containing the K216 gene was isolated from an agarose gel by electroelution. Ap-
proximately 200 copies were injected into the nuclei of C3H/HeN zygotes as previously de-
scribed (16). Founder mice and offspring were confirmed as containing the transgene by
Southern blot analysis of DNA isolated from tails.
Southern Blotting.
￿
DNA was extracted from tumor cell lines grown in vitro or from tail
cells; DNA was digested to completion using an excess of restriction enzyme (New England
Biolabs, Beverly, MA). The digested DNA was then separated on a 0.9% agarose gel and
blotted onto Zetabind membrane (AMF Cuno, Meriden, CT) by capillary flow using 20 x
SSC as transfer buffer. The conditions of the hybridization and the origin of the MHC class
I-specific probe 149.6-6 have been described (10).
Tumor Transplantation, Removal, and Readaptation to Culture.
￿
For tumor challenges, solid tu-
mors grown in nude C3H mice that had been inoculated with cultured cells were implanted
subcutaneously as 1-mm' fragments with a 13-gauge trocar. Deep anesthesia was induced
by inhaled ethylether and chloral hydrate (240 mg/kg body weight) intraperitoneally. Fine
needle biopsy aspirations ofthe tumors were done on anesthetized mice using a 10-ml syringe
fitted with a 20-gauge, 1.5-inch needle. The plunger was withdrawn to the 9-ml mark to create
maximal suction and two or three different locations of the tumor were sampled this way
without withdrawing the needle tip from the initial insertion site in the tumor. The aspirates
were expelled into CMEM containing gentamycinand cultured for a few days before analysis.
Transplantation ofNormal Tissues.
￿
Skin for grafting was obtained from the ventral surface
of the donor mouse and applied to the dorsal thoracic wall according to an adaptation of
the method of Billingham and Medawar (17). Bandages were removed on day 7 and grafts
were scored daily until rejection (defined as loss ofat least 80% of grafted tissue) or the end
point ofthe experiment. Tissues forfetalgut or heart transplants were removed from 16-20-d-
old embryos. Fetal gut tissue was minced with a curved scissors into 1-2-mm3 sections, and
three to four fragments of fetal gut or whole fetal heart were implanted through an incision
5 mm caudal to the base of the ear and moved close to the tip of the ear to allow easy inspec-
tion. Rejection or acceptance o£graft was confirmed histologically 3-5 wk aftertransplantation.
Induction of Cytolytic T Cells In Vivo and In Vitro.
￿
Polyurethane sponge matrix grafts (0.5
cm3; Future Foam Co., Chicago, IL) were transplanted as described (18) into anesthetized
mice by passing the sponge graft through a subcutaneous tunnel and depositing it in the
interscapular region. 5-10 x 106 stimulator cells were injected into the center of the sponges
with a 25-gauge needle and at various times thereafter sponges were removed and placed
into 5 ml ofcold RPMI 1640 containing 5 U ofheparin/ml. Cells to be used as effector cells
in a "Cr-release assay were removed by squeezing the sponge with a forceps multiple times.
In addition, a small fragment of the sponge was cultured to test for possible bacterial contam-
ination of the removed implant. For the generation of cytolytic lymphocytes in vitro, tumor-
bearing or tumor-free mice were first immunized by injecting subcutaneous sponges or the
peritoneal cavity with mitomycin C-treated or untreated tumor cells or spleen cells. At the
time mice were killed, sponges were examined for absence of tumor growth since at the dose
used tumors may occasionally grow out; however, no tumors have ever been observed in mice
injected intraperitoneally with viable tumor cells. Spleen cells were restimulated in vitro in
a mixed lymphocyte tumor cell culture (MLTC) as previously described (14). Cytotoxicity
was determined by the ability of effectors to lyse S'Cr-labeled target cells during a 6-h assay
as previously described (14). The percentage specific lysiswas calculated by the formula: [(ex-
perimental release - spontaneous release)/(maximum release - spontaneous release)] x 100.
Thymocyte and DC Preparations.
￿
Thymocyte suspensions were prepared using the same
methods as used for spleen cell preparations for an MLTC (13). DC preparations were pre-
pared as described (19). Briefly, spleen cells were adhered to plastic culture dishes for 2 h
and the nonadherent cells were removed by washing the plate three times with fresh medium.1208 INDUCTION OF IMMUNE RESPONSES IN THE TUMORBEARING HOST
The adherent macrophages and DC were incubated for an additional 22 h. DC detach during
this second incubation so that the nonadherent cells recovered consist of N50-60% DC. For
convenience, the cells in this preparation that contain NI to 2% of all nucleated cells present
in a normal spleen are referred to as DC.
Flow Cytometric Analyses Cell Preparations.
￿
The antibody CP28, specific for the K216 gene,
has been described (20). The anti-MHC classI mAbs were gifts from Keiko Ozato (National
Institutes ofHealth, Bethesda, MD) and theirspecificities have been described (21). The FAGS
IV (Becton Dickinson & Co., Mountain View, CA) or EPICS-753 (EPICS Coulter Corp.,
Hialeah, FL) was used to quantify the degree of MHC class I antigen expression of tumor
cells or normal transgenic cells. Cells were incubated with MHC class [-specific antibodies
first and then with fluorescein-coupled goat anti-mouse Ig antibodies. The binding ratiowas
determined as the amount of fluorescence after staining with both antibodies divided by the
amount of fluorescence after staining with the second antibody alone.
Results
Generation of Transgenic Mice Expressing the K"6 MHC Class I Antigen.
￿
Transgenic
mice were generated by microinjecting fertilized C3H/HeN oocytes with the Kus
gene. DNA isolated from tails of the offspring was analyzed by Southern blotting.
Fig. 1 A shows that two of seven animals contained a 950-bp polymorphic fragment
characteristic of the K2" gene. To establish two independent K216-transgenic lines
of mice, these two male founder mice were mated to normal C3H/HeN female mice.
Fig. 1 B left panel shows that thymocytes from K216 gene-positive offspring ex-
pressed the K216 antigen in addition to the endogenous normal Kk and Dk MHC
class I antigens. The transgenic mice also expressed the K216 antigen on all cell types
tested including dendritic cells (Fig. 1 B, right), fibroblasts, hepatocytes, kidney cells,
spleen cells, and white blood cells; the peripheral blood cells were used to identify
K216 antigen-positive offspring by flow cytometric analysis. The level of expression
in the normal transgenic tissues was in the range of 10-20-fold above the level of
fluorescence of cells stained with the fluorescein-coupled goat anti-mouse Ig anti-
body alone, quite comparable to levels of expression of the K2" antigen in the pa-
rental 1591-RE tumor (20) or 1591-PRO tumor cells that have been transfected with
the K216 gene (13).
K"6-Trarugenic Skin Is Rejected by Normal C3H1HeNMice.
￿
Several experiments were
performed to test the immune response of normal C3H/HeN mice to K216 trans-
genic tissues. As can be seen in Table 1, normal C3H/HeN mice rejected K216_
transgenic skin after the same time interval as they rejected fully MHC 1-disparate
allogeneic skin grafts. A possible trivial explanation for the highly effective rejection
of the transgenic skin by normal mice might be that expression of additional anti-
gens had been induced by insertional mutagenesis and that the rejection of the K216-
transgenic skin was not specific for the K216 antigen. However, Table I also shows
that the independent lineages of K216_transgenic mice derived from two different
microinjected oocytes accepted skin grafts exchanged between them suggesting that
no additional, artificially generated antigens contributed to the efficient rejection.
In addition, polyurethane sponges placed under the skin of normal mice and in-
jected with K216_transgenic spleen cells led to the generation of sponge-infiltrating
lymphocytes that lysed the K2"-transfected tumor cells but not untransfected pro-
gressor tumor cells. Also, spleen cells from these K2"-immunized mice gave rise
in culture to CTL that specifically killed the K2"-positive tumor cells when restim-
ulated in vitro with the K216_transgenic spleen cells (datanot shown). Together, thesePERDRIZET ET AL.
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experiments suggestthat normal C3H/HeN mice rejected thetransgenic grafts with
the same efficiency as fully allogeneic skin grafts in a K216-specific way.
Mice Bearing a Proggressor TumorDo Not Reject a K216positive Tumor butDo Reject Non-
malignant Grafts Expressing the Same Antigen. Table II shows that mice bearing an es-
tablished 1591-PRO tumor (K216-negative) fail to reject K216-positive 1591 regressor
tumors or 1591-PRO tumors transfected with the K216 MHC class I gene (encoding
the antigen for tumor rejection). An important finding, shown in Table II, is that
even though the progressor tumor-bearing mice failed to reject K216-positive tumors,
these PROTBA's regularly rejected K216_transgenic skin grafts as rapidly as they
rejected allogeneic skin grafts. Both types of grafts were rejected by the PROTBA
with only a slight delay of 1-2 d as compared with the time required for normal
tumor-free mice.
It is conceivable that differences between the proliferative state ofthenormal and
malignanttissues were responsible forthedifferencesbetween the responseoftumor-
bearing mice to K21'-positive skin versus K216_positive tumors, thus favoring tumor
outgrowth. However, Table II showsthat these TBA rejected allogeneic tumors that
rapidly proliferatedand formed tumors before theywere rejected. Furthermore, these
TBA also rejected K211-positive fetal gut transplants from K216-transgenic mice.
These fetal gut transplants showed histologically high mitotic activity and formed
tumor-like masses of 3-10 mm in diameter in syngeneic transgenic controls. Thus,
differences in the proliferative state of the transplanted tissue cannot account for
the different responses ofTBAs to transplanted normal and malignant tissues.
Progressor Tumor-bearing Mice Generate K216_specic CTL in Response to the Antigen on
Normal ButNot on Malignant Cells. Since progressor tumor-bearing mice accepted
K216-positive tumors but rejected K2"-positive skin grafts, we explored whether
these differences correlated with differences in the cytolytic T cell response to the
K216 antigen on normal or malignant cells. K216-transfected tumor cells or K216_
TABLE I
K216 Skin Grafts are Rejected by Normal C3H/HeN Mice but Survive
Indefinitely in Independently Derived K216-Transgenic Lines ofMice
" Day of rejection as mean t standard deviation.
t Represents mice killed at some time after the day indicated. All animals had normal soft
grafts with new hair growth at the time they were killed.
Recipient
Strain
MHC I
haplotype
Donor of skin graft
MHC I
Strain haplotype
Take
of
graft
Survival
of
graft
d t SD'
C3H/HeN KkDk C57BL/6 KbD6 0/5 12 t 0
C3H/HeN transgenic KkDkK216 0/5 12 t 0
line 1
C3H/HeN KkDk 5/5 >901
C3H/HeN transgenic KkDkK216 C3H/HeN transgenic KkDkK216 5/5 >loot
line 1 line 1
C3H/HeN transgenic KkDkK216 5/5 >1001
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FIGURE 1 .
￿
Derivation of transgenicC3H mice containing the K216 gene in their genome and
coexpressing the K216 gene-encoded antigen with the endogenous Dk and K k antigens . (A)
Southern blot analysis of tail DNA from seven mice born after the fertilized oocytes had been
injected with the K216 gene (left) . The right panel showsaSouthern blot analysis ofsix offspringTABLE 11
Mice Bearing K216-negative Tumors Reject K2/6-positive Grafts of
Nonmalignant Tissues but Fail to Reject K216-positive Tumor Grafts
PERDRIZET ET AL.
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" C3H/HeN mice (KkDk) were injected with three 1-mm3 fragments of the K216-negative progressor tumor
1591-PRO at one subcutaneous site (right flank). 4-5 wk later, when tumors had reached an average volume
of 2-5 cm3, these tumor-bearing mice were then challenged with the type of tissue indicated.
t Day of rejection as mean f standard deviation.
S This K216-negative progressor tumor also designated at 1591-PRO represents the 1591 progressor tumor
variant that has lost K226, Dg, and L9 and is used for transfection. Here it is used as untransfected control
tumor. For further details on derivation of this tumor see Materials and Methods.
II 1591-PRO transfected with the K216 gene.
transgenic spleen cells were injected intothe subcutaneous sponge implantsofPRO-
TBA. Two animals in each group were killed 7, 11, 15, and 17 d later to isolate and
test the infiltrating lymphocytes. The PROTBA failed to mount a K21'-specific
CTL response to the K216-positive tumor cells but did mount a K216-specific CTL
response to K216-transgenic spleen cells with a peak response observed at about day
derived from a cross between the founder animal TI and a normal C3H mouse. The Southern
blots were done with Pst I-digested genomic DNA and probed with the class I-specific robe
149.6-6 (10). The presence of a 950-bp polymorphic band indicates the presence of the K21 gene
(10). 1591-RE DNA containing the class I genes L4, D9, and K211 was used as a control. The
size markers are indicated by numbers in kilobases. (B) Flowcytometric analysis of splenic den-
dritic cells of normal or K2t6-transgenic mice of the TI lineage (line 1) (rightpanels) and thymo-
cytes (leftpanels) from transgenic C3H mice of the T5 lineage (lane 2) derived from founder mice
T5 described in A. The cells were incubated with the mAbs CP28 (K216 antigen), 11-4.1 (Kk an-
tigen), and/or 15-5-5 (Dk antigen) followed by incubation with a fluorescein-labeled goat anti-
mouse antibody.
Host"
Strain
Tumor
burden'
Challenge
Type of tissue
MHC I
haplotype
Take
of
graft
Survival
of
graft
d t SDt
C3H/HeN 1591-PRO K2t6+ transfected tumorll KkDkK2t6 5/5 -
(KkDk) tumor 1591-RE tumor KkDkK216DgL4 5/6 -
(KkDk)s 5128-PRO BALB/c tumor KdDd 0/6 -
5117-RE BALB/c tumor KdDd 0/7 -
P815 DBA/2 tumor KdDd 0/5 -
K2t6, transgenic fetal gut KkDkK2t6 0/8 -
K2t6+ transgenic fetal heart KkDkK2t6 0/5 -
K2t6+ transgenic skin KkDkK2t6 0/13 14 f 1
BALB/c skin KdDd 0/6 14 f 1
C57BL/6 skin KbDb 0/9 14 t 0
None K2t6+ transfected tumorll KkDkK2t6 0/6 -
1591-RE tumor KkDkK216D9Lg 0/6 -
K2t6" transgenic skin KkDkK2t6 0/6 13 f 1
BALB/c skin KdDd 0/4 12 t 2
C57BL/6 skin KbDb 0/6 12 t 2
C3H/HeN None K216+ transgenic skin KkDkK2t6 5/5
transgenic K216, transgenic gut KkDkK2t6 5/5
(KkDkK2t6) K2t6" transgenic heart KkDkK2t6 3/31212 INDUCTION OF IMMUNE RESPONSES IN THE TUMOR-BEARING HOST
15. Fig. 2 gives an example ofthe differences observed 15 d after injection ofmalig-
nant or normal stimulator cells. Spleen cells of these TBA were then restimulated
in vitro with K2t6_transgenic spleen cells or the K216-transfected mitomycin
C-treated tumorcells. Fig. 3 showsthat culturesofspleen cellsfrom progressortumor-
bearing mice responded with K2"-specific CTL when the cells had been stimulated
by K2t6_transgenic spleen cells (A-D), but not when stimulated with the K2t6-
positive tumor cells in vivo and in vitro (E-G). K216-positive tumor cells, however,
effectivelystimulated the in vitro generation ofK2t6_specific CTL from spleen cells
of tumor-free K216-immune mice (Fig. 4).
K"6 Regressor Tumor-bearing Mice Which Reject K2`Skin Nevertheless Do Not Selectfor
Antigen Loss Variants. We have shown previously that the K"'-negative progressor
tumor grows at about an 80% incidence when transplanted into tumor-free mice
(14). Ifthe K216 antigen is the only antigen that causes the change from progressor
to regressor phenotype, then the K"'-positive and the K216-negative tumors should
grow at about the same 80% tumor incidence in K216 transgenic mice, and this ap-
pears to be the case, Table III.
We have shown previously (6) that K216-positive regressor tumors injected into
progressor tumor-bearing mice grow progressively, even if the progressor tumor is
subsequently removed (9 d or longer after challenge with the regressor).4 Though
the tumor grows as an antigen-positive tumor in these mice (7), nevertheless the
mice rejected K216-positive transgenic skin (Table III), shown in the followingway.
N
m
U
ca
0
.
T
J
ANTI-K216 RESPONSE OF PRO TBA IN VIVO
80
40
0
80
40
80
40
0
80
40
0
3
￿
12
￿
50 3
￿
12
￿
50
Effector-to-Target Cell Ratio
FIGURE 2.
￿
Generation of an-
tigen-specific CTL in vivo by
tumor-bearingmice in response
to the antigen on normal cells
(A-D)andfailure to respondto
thesame antigen on malignant
K216 spleen cells cells (E-H). Each panel repre-
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ANTI-K216 RESPONSE OF PRO-TBA IN VITRO
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FIGURE 3.
￿
Generation of antigen-specific CTLin vitro from spleen cells oftumor-bearingmice
primed in vivo and restimulated in vitro with the antigen on normal cells (A-D), and failure
of tumor-bearing mice to respond in vitro when primed in vivo and restimulated in vitro with
the same antigen but on malignant cells (E-G). Each panel represents an individual animal.
Allanimals had PRO tumors growing for 4 wk (average size 2-5 cm') when 0.5-1 x 107 K216-
positive spleen cells (A-D) or K216-transfected tumor cells (E-G) were injected into either the
intraperitoneal cavity (B, C, E, G) or subcutaneous sponge matrix grafts (A, D, F). 14-17 dlater
spleen cellswere harvestedandrestimulated in vitroat theoptimalresponderto stimulator (R/S)
ratio with the same form of antigen they received in vivo (A-D, K216-positive spleen at a 30:1
R/S ratio; E-G, K216-transfected tumor cells at a 300:1 R/S ratio). All cultures were analyzed
after 6 d of incubation using 1591-RE tumor cells as the K216-positive target and PRO tumor
cells as the K216-negative control target in a 6-h "Cr-release assay.
Progressor tumor fragments were first injected into the right flank of mice. After
4-5 wk of growth, fragments of the K216-transfected tumor were implanted subcu-
taneously in the contralateral left flank. 10-14d after challenge with the K216_positive
regressor tumor, the progressor tumor was excised. 5-7 d after removal of the pro-
gressor tumor the mice received a transplant of K216-positive skin. These mice re-
jected K216 skin but more slowly than normal recipients. The delay did not seem
to correlatedirectly with the size ofthe regressor tumor nor to theduration oftumor
engraftment (data not shown); nor was the delay specific for the K2` antigen since
rejection of allografts was similarly delayed (Table III). Nevertheless, all of the K216-
transgenic skin grafts were rejected by the mice bearing K216-positive tumors. Sur-
prisingly, however, none ofthesemice rejected theirtumors even though cytofluoro-
metric analysis of cellsisolated by biopsy of the tumor showed that the tumors were
K216-positive at the time when the skin was transplanted (data not shown). Tumors
were biopsied again at the time of rejection of the K216-positive skin graft or during
the following 3 wk, and tumor cell lines were readapted to culture and analyzed1214 INDUCTION OF IMMUNE RESPONSES IN THE TUMOR-BEARING HOST
ANTI -K2ts RESPONSE IN VITRO
OF K216-IMMUNE TUMOR-FREE MICE
Effector-to-Target Ratio
Stimulators
in vivo and vitro:
K216 normal cells
Stimulators
in vivo and vitro
K216 tumor cells
FIGURE 4.
￿
Generation of specific cytolytic T cells in vitro from spleen cells oftumor-free mice
primed in vivo with the antigen on normal tissues (A, spleen; B, skin; C, HLF) or on K216-positive
tumorcells (D, 1591-RE tumorcellsinjected into a subcutaneous polyurethane sponge;E, 1591-
RE tumor cells ip; F, K216-transfected tumor cells i.p.). Tumor-free animals were injected with
0.5-1 x 101K216-tumor cells (D-F), K216-positive normal cells (A, C), or graftedwith K216-positive
skin (B) from K216 transgenic mice. 5-14 d later spleen cells were harvested and restimulated
in vitro at theoptimal R/Sratio with K216 tumorcells (D-F)at a300:1 R/S ratio; or K216 normal
spleen cells (A-C) at an R/S ratio of 30:1 . All cultures were analyzed after 6 d of incubation
using the 1591-RE tumor cells as the K2I6-positive target and PRO tumor cells as the K2"-
negative control target in a 6-h "Cr-release assay.
by flow cytometry for expression of the K216 antigen (Fig. 5). In only one animal
did the tumor show partial but significant K2" antigen loss after rejection of the
K216-positive skin graft.
From previous experiments, we know that K216 antigen loss occurs before the
K216-transfected tumors can grow in immunocompetent mice (13) and that K216 an-
tigen expression is not lost after prolonged growth ofthese tumors in T cell-deficient
hosts such as nude mice or progressor TBA (8). We do not have sufficient concurrent
controls to suggest that this observation of partial loss in one of the tumors was due
to induction of immunity to the K2" antigen by the skin graft. Even if this was so,
it is very striking that all the other K" tumor-bearing mice failed to show any evi-
dence of immunoselection in the progressively growing K216 tumors, despite the fact
that all of these tumor-bearing mice generated sufficient K216-specific immunity to
reject skin grafts expressing the same K216 target antigen.
Discussion
We demonstrate that immune responses to a model tumor antigen, the immuno-
genic MHC class I antigen K216 can be induced in hosts with long term (,>3 wk)TABLE III
Mice Bearing K216positive Tumors Reject K216-positive Skin Transplant but Show
Delayed Skin Graft Rejection Compared with Nonimmune Tumorfree Mice
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C3H/HeN mice (KkDk) 3 wk after implantation and establishment of the 1591-RE or K216 tumors were
challenged with a second K216 tumor or full-thickness skin grafts from K216-transgenic or KbDb allogeneic
donor mice as indicated.
1 Day of rejection as mean t standard deviation.
established tumors by presenting thetumorantigen on normal cells or tissues. How-
ever, these induced responses failed to cause rejection of the tumors though tumor-
bearing animals rejected nonmalignant tissue grafts expressing the same K216 an-
tigen. Furthermore, rejection of the K"'-positive skin grafts was not accompanied
by any reduction in tumor size, or percentage of K216-positive cells in the tumors
of these mice. The rejection of K21'-positive transgenic or allogeneic skin was de-
layed by 1-2 d in the progressor tumor-bearing mice, or by 4-8 d in the K216_
positive regressor tumor-bearing mice; nevertheless, both types of animals rejected
the MHC class I-disparate skin grafts. There was also no evidence for an antigen-
specific enhancement by tumors since mice bearing the K216-positive tumors re-
jected K211-positive grafts or K21'-negative allografts expressing different MHC class
I antigens at about the same time.
Three reasons that are commonly proposed to explain the failure of the immune
system to destroy established tumors: (a) lack of a strong rejection antigen, (b) re-
lease oflargeamounts oftumorantigen causinghost immune cellsto become refrac-
tory, and (c) rapid proliferation of tumor cells that outstrips the capacity of the im-
mune system to respond effectively. Ourexperiments suggest that none ofthese three
mechanisms are very important in the present model.
The target antigen clearly had the strong antigenicity of an MHC class I alloan-
Strain
Host*
Tumor
burden
Challenge
Type of tissue
MHC I
haplotype
Take
of
graft
Survival
of
graft
d t SDz
C3H/HeN 1591-RE tumor K216* transfected tumor KkDkK216 7/7
(KkDk) (KkDkK216DgLq)
K216* transgenic skin KkDkK216 0/13 20 t 4
K216 tumors C57BL/6 skin KbDb 0/6 17 f 1
(KkDkK216)
K216. transgenic skin KkDkK216 0/8 18 ± 6
C57BL/6 skin KbDb 0/5 16 t 1
None K216+ transgenic skin KkDkK216 0/7 12 t 1
K216+ transfected tumor KkDkK216 1/20
C3H/HeN None K216+ transgenic skin KkDkK216 9/9 >100
transgenic
(KkDkK216)
K216* transfected tumor KkDkK216 14/18
1591-PRO tumor KkDk 13/16
(untransfected)
C57BL/6 None C57BL/6 skin KbDb 6/6 >100
(KbDb)1216 INDUCTION OF IMMUNE RESPONSES IN THE TUMOR-BEARING HOST
Day of Rejection of Skin Graft
FIGURE 5.
￿
K` tumors growingin mice that re-
ject K2"-positive skin grafts continue to express
K216 target antigen. K216-RE TBA were chal-
216 lenged wuh K -posttlve transgenlc skm, and
2 wk after rejection of the skin all tumors were
sampled by fine needle aspiration biopsy. These
tumorcells were readaptedto tissue culture and
stained with the K216-specific mAb CP28 (20)
andanalyzed by flow cytometry. Thepercentage
of tumor cells that express the K216 antigen is
presentedon they axis and the day ofskin graft
rejection is listed on thexaxis. Despite the ability
ofthe K216-RE TBAto reject the K216 skin graft
thereisonly oneexamplewherethis response was
associated with significant selection against the
K216 antigen expression by a tumor growing in
the same animal.
tigen in that it caused tumor regression in mice even when challenged with large
amounts of tumor tissue without prior immunization. (And we do not consider it
likely that human tumors will be more antigenic.) If large amounts of antigen due
to the tumor load prevented the stimulation or effector function of anti-K
216 T cells,
then these mice should not have been able to reject the K216-positive transgenic skin
grafts. Though the rejection of K216-positive skin was delayed in the K` TBA, these
mice showed a similar delay of rejection of antigenically unrelated allogeneic skin
grafts, which is consistent with the apparent absence of antigen specificity of the
suppression in the TBA (7). If the proliferative capacity of the tumor was simply
greater than the killing capacity of the immune response generated, then anti-K
216
immunity caused by K216-positive skin rejection should have caused some slowdown
in
K216 tumor growth. Alternatively, at least some evidence for immune selection
for K216 loss variants should have been found after weeks of continued tumor growth
in the nominally immune mice. Selection for variants readily occurs in the absence
of a detectable effect on tumor size in short-term UVirradiated mice (22) or in
X-irradiated, thymectomized, spleen cell-reconstituted mice with partially compro-
mised but still demonstrable tumor antigen-specific immunity (8). Thus, selection
for antigen loss variants appears to be a particularly sensitive measure of antitumor
immunity. The observed absence of selection seen here strongly suggests the ab-
sence of any antigen-specific tumorcell destruction in the tumor, and it is therefore
unlikely that the tumor simply grew because it outstripped the killing capacity of
the immune system. Certainly, differences in the mitotic activity ofthe transplanted
tissues seem not to be sufficient to explain why TBA reject transgenic skin, since
TBA also rejected K216-positive fetal gut transplants that display a very high mi-
c
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totic index. Together, our experiments fail to support the notion that low antige-
nicity, large antigen load, or inadequate proliferative capacity of the immune cells
(as compared with the tumor) were responsible for the failure of the anti-K216 im-
munity to be effective.
At present, we do not know why TBA fail to reject the K216 tumors when these
animals rejected nonmalignant tissue transplants expressing the same target antigen.
Kaliss (23) noted many years ago that it was considerably easier to enhance tumor
allografts than normal tissue allografts with alloantisera and he suggested that the
ability of tumors to be enhanced more easily "characterizes a fundamental differ-
ence between cancerous and normal tissues." Possibly grafts of normal tissues are
rejected consistently because they contain Langerhans cells, which are absent in tu-
mors but which can powerfully stimulate allogeneic responses (24). Even though
the tumor-free host can reject regressor tumors despite an absence of Langerhans
cells or dendritic cells, antigen presentation by such cells may be important for the
rejection by host with enhanced allografts. For example, injection of dendritic cells
can abruptly terminate long-term allograft enhancement (25, 26). Although den-
dritic cells pulsed with lyophilized tumor antigen failed to induce tumor rejection
(27) it is not knownwhetherdendritic cellstransfected to express tumor-specific an-
tigens can lead to rejection of an established cancer.
Local factors at the tumor site may prevent immune cells from entering and re-
jecting tumor grafts, and the nature and specificity of tumor infiltrating lympho-
cytes need to be determined. Malignant cells are metabolically very active and can
produce substances that maybe immunosuppressive by inhibiting leukocyte attrac-
tion, antigen presentation, or effector function of Tcells. Such substances produced
at thesite oftheestablished tumormayact as alocal barrierto infiltration by tumor-
specific lymphocytes and/or prevent immune destruction. Such substances couldre-
duce systemic immune reactivity, and the fact that TBA showed delayed allogeneic
skin rejection is consistent with some degree of systemic immune suppression. In
previous studies, we have shown that mice bearing UVinduced tumors have sup-
pressor lymphocytes that can prevent the tumor rejection of regressor tumors by
normal host lymphocytes upon adoptive transfer (7, 8). Such suppresser cells in-
duced by malignanttissuesmight possibly lead to localintratumor suppression; how-
ever, the specificity andfunction ofthese suppressor cellsthat areabsent from athymic
tumor-bearing mice remains to be determined.
There are some interesting parallels between allograft and tumor enhancement.
Pregnant individuals reject paternal skin allografts without aborting (28, 29), and
rats harboring long-term enhanced renal allografts reject donor type skin without
rejecting the renal transplants (30). In both instances, the survival time of the skin
graft is slightly prolonged, similar to that observed for K216-positive skirt grafts in
the mice carrying K216-positive tumors. While some of the parallels between the
different systems are striking, none of the systems have resolved the precise mecha-
nisms for: (a) the enhancement of the primary graft, (6) the slight prolongation of
the secondary graft, and (c) the failure of immune cells that must participate in re-
jecting the second graft to affect the survival of the first graft. Possibly the tumor
escapes through a loophole in the immune defense that had to be left open because
allogeneic fetuses must not be rejected by the pregnant mother. Thus, if we can un-1218 INDUCTION OF IMMUNE RESPONSES IN THE TUMORBEARING HOST
derstand why the mother fails to reject her fetus we may learn why an individual
fails to respond to immunogenic tumors.
Whatever the mechanism(s) underlying our observations, it appears that responses
can be induced in the TBA by presentingthe "tumor" antigen on nonmalignant rather
than malignant tissues. A potentially powerful approach to be used in the future
may be the genetic transfer ofthe expression of a tumor antigen into nontumor cells,
particularly into cells that have potent immunostimulatory activity, such as den-
dritic cells (31). Although induction oftumor-specific immune responses in the tumor-
bearing host may be essential for tumorrejection, additional therapeutic manipula-
tions may be required to cause immunological rejection of established tumors.
Summary
Breaking the state of immunological unresponsiveness of tumor-bearing individ-
uals to cancer is a prerequisite for active or passive tumor-specific immunotherapy.
To study this problem the immunogenic MHC class I antigen,
K216 was transfected
into a progressor tumor. The transfected tumors were regularly rejected by normal
mice but grew progressively in mice bearing nontransfected tumors. In addition,
transgenicmice were derived to obtain normal cells and tissues expressing the same
K216 gene product. Normal mice rejected
K 216-positive normal or malignant tissue
grafts and generated K 216-specific CTL in vitro and in vivo in response to these chal-
lenges. In contrast, mice bearing nontransfected tumors, though rejecting K
216_
positive nonmalignant tissue grafts, did not reject K 216-positive tumors nor generate
K2"-specific CTL in response to K 216-positive tumor cells. Mice bearing K
211_
positive tumors also rejected the nonmalignant
K 216-positive tissue grafts, but this
in vivo response failed to lead to rejection of the simultaneously present tumor graft
expressing the same antigen; in fact, immunity had no measurableeffect whatsoever
on tumor size or incidence and caused no selection for antigen loss variants. Taken
together, the present findings suggest that transfer of expression of a target antigen
into nonmalignant cells provides a way for obtaining effective stimulation ofantigen-
specific CTL in tumor-bearing mice, but that additional manipulations will be re-
quired to cause immunological rejection of established tumors.
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Receivedfor publication 23 August 1989 and in revisedform 29 December 1989.
References
1 . Prehn, T T, and T. M. Main. 1957. Immunity to methylcholanthrene-induced sarcomas.
J. Nail. Cancer Inst. 18 :769.
2. North, R. J . 1985 . Down regulation of the anti-tumor immune response. Adv. Cancer
Res. 45:1 .
3 . Klein, G. H., H. O. Sjogren, E. Klein, and K. E. Hellstr6m. 1960. Demonstration of
resistance against methylcholanthrene-induced sarcomas in the primary autochthonous
host. Cancer Res. 20:1561.
4. Kripke, M. L. 1974. Antigenicity of murine skin tumors induced by ultraviolet light.
J. Nail. Cancer Inst. 53:1333 .PERDRIZET ET AL.
￿
121 9
5. Fujimoto, S., M. 1. Greene, and A. H. Sehon. 1976. Regulation of the immune response
to tumor antigens. I. Immunosuppressor cells in tumor-bearinghosts. Immunology. 116:791.
6. Berendt, M. J., and R. J. North. 1980. Tcell-mediated suppression of anti-tumor im-
munity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med.
151 :69.
7. Mullen, C. A., T L. Urban, C. Van Waes, D. A. Rowley, and H. Schreiber. 1985. Mul-
tiple cancers: tumor burden permits outgrowth of other cancers. J Exp. Med. 162 :1665 .
8. Mullen, C. A., D. A. Rowley, and H . Schreiber. 1989. Highly immunogenic regressor
tumor cells can prevent development ofpostsurgical tumor immunity. Cell. Immunol 119:101.
9 . Fisher, M. S., and M. L. Kripke. 1977. Systemic alteration induced in mice by ultraviolet
light irradiation and its relationship to ultraviolet carcinogenesis. Proc. Natl. Acad. Sci.
USA. 74:1688.
10 . Stauss, H. J., R. Linsk, A. Fischer, D. Banasiak, A. Haberman, I. Clark, J. Forman,
M. McMillan, H. Schreiber, and R. S. Goodenow. 1986. Isolation of the MHC genes
encoding the tumor-specific class I antigens expressed on murine fibrosarcoma.J Immu-
nogenet. 13:101.
11 . Lee, D. R., R. J. Rubocki, W. R. Lie, and T H. Hansen. 1988. The murine MHC
class I genes, H-2DQ and H-2L9 are strikingly homologous to each other, H-2L', and
two genes reported to encode tumor-specific antigens. J Exp. Med. 168 :1719.
12 . Linsk, R., J. Vogel, H . Stauss, J. Forman, and R. S. Goodenow. 1986. Structure and
function of three novel MHC class I antigens derived from a C3H ultraviolet light-in-
duced fibrosarcoma. J Exp. Med. 164:794.
13 . Stauss, H. J., C. Van Waes, M. A. Fink, B. Starr, and H. Schreiber. 1986. Identification
of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer.
J Exp. Med. 164:1516.
14. Urban, J. L., R. C. Burton, J. M. Holland, M. L. Kripke, and H. Schreiber. 1982. Mech-
anism of syngeneic tumor rejection. Susceptibility of host selected progressor variants
to various immunological effector cells. J Exp. Med. 155:557.
15. Ward, P. L., H. Koeppen, T. Hurteau, and H. Schreiber. 1989. Tumor antigens defined
by cloned immunological probes are highly polymorphic and are not detected on autolo-
gous normal cells. J Exp. Med. 170:217.
16. Ross, S. R., and D. Solter. 1985. Glucocorticoid regulation of mouse mammary tumor
virus sequences in transgenic mice. Proc. Nad. Acad. Sci. USA. 82:5880.
17. Billingham, R. E., and P B. Medawar. 1951. The technique offree skin grafting in mam-
mals. J Exp. Biol. 28:385.
18. Ascher, N. L., R. M . Ferguson, R. Hoffman, and R. L. Simmons. 1979. Partial charac-
terization of cytotoxic cells infiltrating sponge matrix allografts. Transplantation (Baltimore).
27:254.
19 . Shah, P D., S. M. Gilbertson, and D. A. Rowley. 1985. Dendritic cells that have inter-
acted with antigen are targets for natural killer cells. J Exp. Med. 162:625.
20 . Philipps, C., M. McMillan, P. M. Flood, D. B. Murphy, J. Forman, D. Lancki, J . E.
Womack, R. S. Goodenow, and H. Schreiber. 1985. Identification of a unique tumor-
specific antigen as a novel class I major histocompatibility molecule. Proc. Natl. Acad. Sci.
USA. 82:5140.
21 . Evans, G. A., D. H. Margulies, B. Shykind, J . G. Seidman, and K. Ozato. 1982. Exon
shuffling: mapping polymorphic determinants on hybrid mouse transplantation anti-
gens. Nature (Loud.). 300:755 .
22 . Urban, J. L., J . M. Holland, M. L. Kripke, and H. Schreiber. 1982. Immunoselection
of tumor cell variants by mice suppressed with UV radiation. J Exp. Med. 156:1025.
23 . Kaliss, N. 1958. Immunological enhancement of tumor homografts in mice. Cancer Res.
18:992.1220 INDUCTION OF IMMUNE RESPONSES IN THE TUMOR-BEARING HOST
24. Inaba, K., J. W. Young, and R. M. Steinman. 1987 . Direct activation of CD8` cyto-
toxic T lymphocytes by dendritic cells. , .. Exp. Med. 166:182 .
25. Lechler, R. I., and J . R. Batchelor. 1982 . Restoration of immunogenicity to passenger
cell-depleted kidney allografts by addition of donor strain dendritic cells. J Exp. Med. 31:155.
26 . Faustman, D. L., R. M . Steinman, H . M. Gebel, V. Hauptfeld,J. M. Davie, and P. E .
Lacy. 1984. Prevention of rejection of murine islet allografts by pretreatment with anti-
dendritic cell antibody. Proc. Natl. Acad. Sci. USA. 81:3864.
27 . Knight, S. C,, R. Hunt, C. Dore, and P. B. Medawar. 1985. Influence of dendritic cells
on tumor growth. Proc. Natl. Acad. Sci. USA. 82:4495.
28. Heslop, R. W., P. L. Krohn, and E. M. Sparrow. 1954. The effect of pregnancy on the
survival of skin homografts in rabbits, J. Endocrinol. 10:325.
29. Lanman, J . T., J . Dinerstein, and S. Fikrig. 1962. Homograft immunity in pregnancy:
lack of harm to the fetus from sensitization of the mother. Ann. NY Acad. Sci. 99:706.
30. Stuart, F. P., F. W. Fitch, and D. A. Rowley. 1970. Specific suppression of renal allograft
rejection by treatment with antigen and antibody. Transplant. Proc. 2 :483.
31 . Steinman, R. M., K. Inaba, G. Schuler, and M. Witmer. 1986 . Stimulation of the im-
mune response: contribution of dendritic cells. In Mechanisms of Host Resistance to
Infectious Agents, Tumors and Allografts. R. M. Steinman and R. J. North, editors.
Rockefeller University Press, New York. 71 .